<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988325</url>
  </required_header>
  <id_info>
    <org_study_id>WP22849</org_study_id>
    <secondary_id>2009-014365-12</secondary_id>
    <nct_id>NCT00988325</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to &lt;12 Months of Age With Confirmed Flu Infection</brief_title>
  <official_title>An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (TamifluÂ®) in the Treatment of Infants 0 to &lt;12 Months of Age With Confirmed Influenza Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics/pharmacodynamics and safety of oseltamivir
      [Tamiflu] therapy in infants less than 1 year of age with influenza diagnosed in the 96 hours
      prior to the first dose. Patients age 3-12 months will receive 3 mg/kg, 1-3 months will
      receive 2.5 mg/kg, and birth to 1 month will receive 2 mg/kg twice a day for a total of 10
      doses. Patients positive for influenza virus on Day 6 will be eligible to receive continued
      study treatment for an additional 10 doses (5 days). The anticipated time on study treatment
      is 4 weeks, and the target sample size is 65-85 male and female infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is active metabolite of oseltamivir. AUC0-12 was estimated for oseltamivir and oseltamivir carboxylate by linear trapezoidal rule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is an active metabolite of oseltamivir. Cmax was estimated for both oseltamivir and Oseltamivir carboxylate by non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state Minimum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is active metabolite of oseltamivir. Cmin was estimated for both oseltamivir and oseltamivir carboxylate by non-compartmental analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.Tmax was estimated using non-compartmental methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half Life of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/-15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Elimination half-life is defined as the time required for elimination of a drug to half its plasma concentration and was computed using non-compartmental method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent First-order Elimination Rate Constant of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is active metabolite of oseltamivir.The apparent first-order elimination rate constant (Lambda Z) was determined by linear regression analysis of terminal data points. A minimum of 3 data points were used for lambda Z estimation. By reporting tool convention, if n&lt;3, no summary statistics were calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Plasma Clearance as a Function of Bioavailability and Apparent Plasma Clearance of the Metabolite as a Function of Bioavailability (CLm/F) of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is active metabolite of oseltamivir. CL/F was calculated as dose/AUCinf, where AUCinf represents the area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Volume of Distribution as a Function of Bioavailability of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is active metabolite of oseltamivir. V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast of Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>The last measurable plasma concentration of oseltamivir and oseltamivir carboxylate was the last quantifiable concentration of oseltamivir or oseltamivir carboxylate, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Last Measurable Plasma Concentration for Oseltamivir and Oseltamivir Carboxylate</measure>
    <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
    <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Neurological Assessment Scores</measure>
    <time_frame>Baseline (Day 1); Day 3 for who received two does on Day 1 or Day 4 for who received one dose on Day 1; Day 6, Day 11, Day 18, Day 30</time_frame>
    <description>Neurological assessment was performed to assess the mental state of the participants through two scales: Infant face scale and Glasgow coma scale. Each scale consists of 3 subscales: eye opening (ranging 1 to 4), verbal response (ranging 1 to 5), and motor responses (ranging 1 to 6). The final score is the sum of these ranges and is scored between 3 and 15. 3 being the worst, and 15 the best. Change from baseline is change of final score post-baseline minus the final score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Cessation of Viral Shedding in Participants With Positive Culture at Baseline</measure>
    <time_frame>Days 1, 3 or 4, 6, 11, 18, and 30</time_frame>
    <description>Median time to cessation of viral shedding was calculated for all patients with positive by culture / by polymerase chain reaction (PCR) at baseline using all data points between the start of the treatment and the 1st time point of negative culture without subsequent positive culture results. These time-to event analyses were only performed for the viral titre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virus Shedding by Virus Type</measure>
    <time_frame>Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days</time_frame>
    <description>The viral titer was measured by culture and reported in log10 (50% tissue culture infective dose [TCID50]). The viral load was analyzed by PCR and reported as log10 particles/mL. The number of patients positive for viral shedding by virus sub-type was measured on specified days from baseline to last visit on Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever in Participants With Fever at the Baseline</measure>
    <time_frame>Days 1 to 11; Day 18; Day 30</time_frame>
    <description>This was performed for all participants who had fever at baseline. Fever is defined as body temperature &gt;37.0 degree Celsius. Rectal temperature is converted by subtracting 1 degree Celsius. Time to Resolution of Fever was defined as the time from the initiation of treatment to first time the afebrile state was reached and maintained for at least 21.5 hours, where afebrile state was defined as axillary temperature â¤ 37 degree Celsius.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Decline of Body Temperature to the Afebrile State</measure>
    <time_frame>Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days</time_frame>
    <description>This was performed for all participants who had fever at baseline Fever is defined as body temperature &gt;37.0ÂºC. Rectal temperature is converted by subtracting 1 ÂºC. The rate of decline of body temperature was calculated as the slope of body temperature between the baseline temperature and the 1st temperature below 37Â°C. Participants with decline in body temperature were considered to have no fever; however, participants who did not show any decline in body temperature were considered to have persisting fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Serious Adverse Events and Secondary Illness</measure>
    <time_frame>Up to 3 days after the last dose of oseltamivir (Approximately 14 days)</time_frame>
    <description>An Adverse Event (AEs) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect. Secondary illnesses were influenza disease-related events, namely bronchitis, pneumonia, otitis media, and sinusitis that resolved without sequelae. Adverse events, serious adverse events, and secondary illness are reported for on-treatment period (from the first dose of oseltamivir upto 3 days after the last dose of oseltamivir [Approximately 14 days].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Showing Within-patient Variability in Vital Signs</measure>
    <time_frame>Post baseline, Day 3, 4, 6, 11, 18+/- 2 days, 30+/-2 days</time_frame>
    <description>Systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, and heart rate were examined for any consistent within-patient post-baseline changes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Oseltamivir 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infants 3 to &lt;12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infants 1 to &lt;3 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infants 0 to 30 days (post natal) of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamiflu</intervention_name>
    <description>oral repeating dose</description>
    <arm_group_label>Oseltamivir 3 mg</arm_group_label>
    <arm_group_label>Oseltamivir 2.5 mg</arm_group_label>
    <arm_group_label>Oseltamivir 2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants &lt;/=12 months of age

          -  laboratory confirmed diagnosis of influenza within 96 hours prior to first dose

          -  influenza symptoms for &lt;/=96 hours prior to first dose

        Exclusion Criteria:

          -  preterm infants less than 40 weeks (corrected for gestational age)

          -  weight less than 5th percentile for age (corrected for gestational age)

          -  concurrent gastrointestinal conditions that preclude enteric absorption of the drug

          -  bronchopulmonary dysplasia/chronic lung disease on assisted ventilation at time of
             enrollment

          -  active or uncontrolled respiratory, cardiac, hepatic, CNS or renal disease at baseline

          -  symptomatic inborn errors of metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Femme MÃ¨re Enfant; Service de rhumatologie pÃ©diatrique</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMPUS VIRCHOW-KLINIKUM CharitÃ©Centrum 17 Klinik f.PÃ¤diatrie Abt.Pneumologie u.Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LWL-Klinik-Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44792</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dr. Med. O. Burkhard &amp; B. Reimann</name>
      <address>
        <city>Worms</city>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny ZakÅad Opieki; WczeÅniakÃ³w I Intensywnej Terapii</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Opieki Zdrowotnej Debica; Oddzial Dzieciecy</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Hedwig Hospital In Trzebnica</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS) ; Intermedios y Urgencias Pediatricas</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La CoruÃ±a</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe; Servicio de Pediatria</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted across 11 centers in Spain, Italy, France, Germany, Belgium, and Poland from 10 January 2011 to 04 April 2012. A total of 65 participants were screened.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oseltamivir 3 mg/kg</title>
          <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 milligram (mg)/kilogram (kg) twice a day for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Oseltamivir 2.5 mg/kg</title>
          <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Oseltamivir 2 mg/kg</title>
          <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all treated participants with at least one post-baseline safety assessment (vital sings like temperature, respiratory rate, blood pressure, pulse rate).</population>
      <group_list>
        <group group_id="B1">
          <title>Oseltamivir 3 mg/kg</title>
          <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>Oseltamivir 2.5 mg/kg</title>
          <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Oseltamivir 2 mg/kg</title>
          <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223.2" spread="79.41"/>
                    <measurement group_id="B2" value="57.0" spread="17.24"/>
                    <measurement group_id="B3" value="25.2" spread="5.36"/>
                    <measurement group_id="B4" value="156.8" spread="105.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is active metabolite of oseltamivir. AUC0-12 was estimated for oseltamivir and oseltamivir carboxylate by linear trapezoidal rule</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is active metabolite of oseltamivir. AUC0-12 was estimated for oseltamivir and oseltamivir carboxylate by linear trapezoidal rule</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
          <units>hour (h)*nanogram(ng)/milliliter (mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir, n=37, 17, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="36.2"/>
                    <measurement group_id="O2" value="194" spread="47.8"/>
                    <measurement group_id="O3" value="142" spread="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate, n=18,11, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4990" spread="27.4"/>
                    <measurement group_id="O2" value="4920" spread="35.3"/>
                    <measurement group_id="O3" value="NA">Geometric Mean and Geometric Coefficient of Variation were not calculated for 2 participants analyzed. Individual data are not reported due to privacy concerns</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.Tmax was estimated using non-compartmental methods</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.Tmax was estimated using non-compartmental methods</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.88" upper_limit="3.08"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.00" upper_limit="2.92"/>
                    <measurement group_id="O3" value="1.08" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" lower_limit="2.08" upper_limit="7.00"/>
                    <measurement group_id="O2" value="2.88" lower_limit="0.00" upper_limit="6.67"/>
                    <measurement group_id="O3" value="5.83" lower_limit="2.58" upper_limit="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Elimination Half Life of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Elimination half-life is defined as the time required for elimination of a drug to half its plasma concentration and was computed using non-compartmental method</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/-15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Elimination Half Life of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Elimination half-life is defined as the time required for elimination of a drug to half its plasma concentration and was computed using non-compartmental method</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir, n= 37, 17, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="38.5"/>
                    <measurement group_id="O2" value="2.01" spread="49.3"/>
                    <measurement group_id="O3" value="1.66" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate, n=18, 11, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.45" spread="53.3"/>
                    <measurement group_id="O2" value="11.3" spread="92.7"/>
                    <measurement group_id="O3" value="NA">Geometric Mean and Geometric Coefficient of Variation were not calculated for 2 participants analyzed. Individual data are not reported due to privacy concerns</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent First-order Elimination Rate Constant of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is active metabolite of oseltamivir.The apparent first-order elimination rate constant (Lambda Z) was determined by linear regression analysis of terminal data points. A minimum of 3 data points were used for lambda Z estimation. By reporting tool convention, if n&lt;3, no summary statistics were calculated</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent First-order Elimination Rate Constant of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is active metabolite of oseltamivir.The apparent first-order elimination rate constant (Lambda Z) was determined by linear regression analysis of terminal data points. A minimum of 3 data points were used for lambda Z estimation. By reporting tool convention, if n&lt;3, no summary statistics were calculated</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol.</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir, n= 33, 11, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.349" spread="39.9"/>
                    <measurement group_id="O2" value="0.338" spread="52.9"/>
                    <measurement group_id="O3" value="0.418" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate, n=17, 7, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0735" spread="55.2"/>
                    <measurement group_id="O2" value="0.0475" spread="110.6"/>
                    <measurement group_id="O3" value="NA">Geometric Mean and Geometric Coefficient of Variation were not calculated for 2 participants analyzed. Individual data are not reported due to privacy concerns</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady-state Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is an active metabolite of oseltamivir. Cmax was estimated for both oseltamivir and Oseltamivir carboxylate by non-compartmental analysis.</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is an active metabolite of oseltamivir. Cmax was estimated for both oseltamivir and Oseltamivir carboxylate by non-compartmental analysis.</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" spread="47"/>
                    <measurement group_id="O2" value="62.5" spread="69.1"/>
                    <measurement group_id="O3" value="25.2" spread="211.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" spread="37.7"/>
                    <measurement group_id="O2" value="530" spread="33.1"/>
                    <measurement group_id="O3" value="501" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady-state Minimum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is active metabolite of oseltamivir. Cmin was estimated for both oseltamivir and oseltamivir carboxylate by non-compartmental analysis</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Minimum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is active metabolite of oseltamivir. Cmin was estimated for both oseltamivir and oseltamivir carboxylate by non-compartmental analysis</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="65.4"/>
                    <measurement group_id="O2" value="2.09" spread="52.6"/>
                    <measurement group_id="O3" value="2.56" spread="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238" spread="43.8"/>
                    <measurement group_id="O2" value="248" spread="51.5"/>
                    <measurement group_id="O3" value="169" spread="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Plasma Clearance as a Function of Bioavailability and Apparent Plasma Clearance of the Metabolite as a Function of Bioavailability (CLm/F) of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is active metabolite of oseltamivir. CL/F was calculated as dose/AUCinf, where AUCinf represents the area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Plasma Clearance as a Function of Bioavailability and Apparent Plasma Clearance of the Metabolite as a Function of Bioavailability (CLm/F) of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is active metabolite of oseltamivir. CL/F was calculated as dose/AUCinf, where AUCinf represents the area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration</population>
          <units>mL/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir, n= 37, 17, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80500" spread="42.8"/>
                    <measurement group_id="O2" value="63000" spread="63.7"/>
                    <measurement group_id="O3" value="50600" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate, n=18,11, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3940" spread="38.8"/>
                    <measurement group_id="O2" value="2180" spread="54.86"/>
                    <measurement group_id="O3" value="NA">Total Plasma Clearance was not calculated for 2 participants analyzed. Individual data are not reported due to privacy concerns</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Volume of Distribution as a Function of Bioavailability of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is active metabolite of oseltamivir. V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Volume of Distribution as a Function of Bioavailability of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is active metabolite of oseltamivir. V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol. n = participants with evaluable drug concentration.</population>
          <units>mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir, n= 37, 17, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234000" spread="66.2"/>
                    <measurement group_id="O2" value="183000" spread="87.9"/>
                    <measurement group_id="O3" value="121000" spread="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate, n=18,11, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53700" spread="78.1"/>
                    <measurement group_id="O2" value="35400" spread="96.5"/>
                    <measurement group_id="O3" value="NA">Geometric Mean and Geometric Coefficient of Variation were not calculated for 2 participants analyzed. Individual data are not reported due to privacy concerns</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clast of Oseltamivir and Oseltamivir Carboxylate</title>
        <description>The last measurable plasma concentration of oseltamivir and oseltamivir carboxylate was the last quantifiable concentration of oseltamivir or oseltamivir carboxylate, respectively.</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated patients with at least one blood sample evaluable for drug concentration level and who were adhered to the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clast of Oseltamivir and Oseltamivir Carboxylate</title>
          <description>The last measurable plasma concentration of oseltamivir and oseltamivir carboxylate was the last quantifiable concentration of oseltamivir or oseltamivir carboxylate, respectively.</description>
          <population>Pharmacokinetic (PK) population included all treated patients with at least one blood sample evaluable for drug concentration level and who were adhered to the protocol</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262" spread="39.2"/>
                    <measurement group_id="O2" value="176" spread="58.3"/>
                    <measurement group_id="O3" value="84.3" spread="154.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3800" spread="50.1"/>
                    <measurement group_id="O2" value="4410" spread="34.0"/>
                    <measurement group_id="O3" value="3940" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Last Measurable Plasma Concentration for Oseltamivir and Oseltamivir Carboxylate</title>
        <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
        <time_frame>15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1</time_frame>
        <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Last Measurable Plasma Concentration for Oseltamivir and Oseltamivir Carboxylate</title>
          <description>Oseltamivir carboxylate is an active metabolite of oseltamivir.</description>
          <population>Pharmacokinetic (PK) population included all treated participants with at least one blood sample evaluable for drug concentration level and who adhered to the protocol.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oseltamivir</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.23" spread="30.1"/>
                    <measurement group_id="O2" value="8.53" spread="32.9"/>
                    <measurement group_id="O3" value="6.94" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oseltamivir carboxylate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.11" spread="21.2"/>
                    <measurement group_id="O2" value="10.64" spread="5.4"/>
                    <measurement group_id="O3" value="10.45" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in Neurological Assessment Scores</title>
        <description>Neurological assessment was performed to assess the mental state of the participants through two scales: Infant face scale and Glasgow coma scale. Each scale consists of 3 subscales: eye opening (ranging 1 to 4), verbal response (ranging 1 to 5), and motor responses (ranging 1 to 6). The final score is the sum of these ranges and is scored between 3 and 15. 3 being the worst, and 15 the best. Change from baseline is change of final score post-baseline minus the final score at baseline.</description>
        <time_frame>Baseline (Day 1); Day 3 for who received two does on Day 1 or Day 4 for who received one dose on Day 1; Day 6, Day 11, Day 18, Day 30</time_frame>
        <population>Safety population included all treated participants with at least one post-baseline safety assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in Neurological Assessment Scores</title>
          <description>Neurological assessment was performed to assess the mental state of the participants through two scales: Infant face scale and Glasgow coma scale. Each scale consists of 3 subscales: eye opening (ranging 1 to 4), verbal response (ranging 1 to 5), and motor responses (ranging 1 to 6). The final score is the sum of these ranges and is scored between 3 and 15. 3 being the worst, and 15 the best. Change from baseline is change of final score post-baseline minus the final score at baseline.</description>
          <population>Safety population included all treated participants with at least one post-baseline safety assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With change in infant face scale measurement score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With change in Glasgow coma scale assessment score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Cessation of Viral Shedding in Participants With Positive Culture at Baseline</title>
        <description>Median time to cessation of viral shedding was calculated for all patients with positive by culture / by polymerase chain reaction (PCR) at baseline using all data points between the start of the treatment and the 1st time point of negative culture without subsequent positive culture results. These time-to event analyses were only performed for the viral titre.</description>
        <time_frame>Days 1, 3 or 4, 6, 11, 18, and 30</time_frame>
        <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Cessation of Viral Shedding in Participants With Positive Culture at Baseline</title>
          <description>Median time to cessation of viral shedding was calculated for all patients with positive by culture / by polymerase chain reaction (PCR) at baseline using all data points between the start of the treatment and the 1st time point of negative culture without subsequent positive culture results. These time-to event analyses were only performed for the viral titre.</description>
          <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.5" lower_limit="118.0" upper_limit="231.0"/>
                    <measurement group_id="O2" value="113.0" lower_limit="63.0" upper_limit="230.0"/>
                    <measurement group_id="O3" value="113.0" lower_limit="110.0" upper_limit="116.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.166</p_value>
            <p_value_desc>p-value is for the comparison of the age cohorts (treatment groups)</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Test was used for testing homogeneity of survival curves</method_desc>
            <param_type>Median time to cessation of viral sheddi</param_type>
            <param_value>119</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>113</ci_lower_limit>
            <ci_upper_limit>230</ci_upper_limit>
            <estimate_desc>Median time was estimated from the Kaplan-Meier curve (unstratified)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virus Shedding by Virus Type</title>
        <description>The viral titer was measured by culture and reported in log10 (50% tissue culture infective dose [TCID50]). The viral load was analyzed by PCR and reported as log10 particles/mL. The number of patients positive for viral shedding by virus sub-type was measured on specified days from baseline to last visit on Day 30.</description>
        <time_frame>Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days</time_frame>
        <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
        <group_list>
          <group group_id="O1">
            <title>Type A (H1N1)pdm09</title>
            <description>Genotype A (H1N1)pdm09 was present in 21 participants of age group 91 to &lt;365 days, 9 participants of age group 31 to 90 days, and 2 participants of age group &lt;=30 days</description>
          </group>
          <group group_id="O2">
            <title>Type A H3</title>
            <description>Genotype Type A H3 was present in 4 participants and 6 participants of age groups 91 to &lt;365 days and 31 to 90 days, respectively</description>
          </group>
          <group group_id="O3">
            <title>Type B</title>
            <description>Genotype B was present in 12, 2, and 2 participants of age groups &lt;365 days, 31 to 90 days, and &lt;=30 days, respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virus Shedding by Virus Type</title>
          <description>The viral titer was measured by culture and reported in log10 (50% tissue culture infective dose [TCID50]). The viral load was analyzed by PCR and reported as log10 particles/mL. The number of patients positive for viral shedding by virus sub-type was measured on specified days from baseline to last visit on Day 30.</description>
          <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 or 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18 +-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 +-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever in Participants With Fever at the Baseline</title>
        <description>This was performed for all participants who had fever at baseline. Fever is defined as body temperature &gt;37.0 degree Celsius. Rectal temperature is converted by subtracting 1 degree Celsius. Time to Resolution of Fever was defined as the time from the initiation of treatment to first time the afebrile state was reached and maintained for at least 21.5 hours, where afebrile state was defined as axillary temperature â¤ 37 degree Celsius.</description>
        <time_frame>Days 1 to 11; Day 18; Day 30</time_frame>
        <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever in Participants With Fever at the Baseline</title>
          <description>This was performed for all participants who had fever at baseline. Fever is defined as body temperature &gt;37.0 degree Celsius. Rectal temperature is converted by subtracting 1 degree Celsius. Time to Resolution of Fever was defined as the time from the initiation of treatment to first time the afebrile state was reached and maintained for at least 21.5 hours, where afebrile state was defined as axillary temperature â¤ 37 degree Celsius.</description>
          <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="9.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="20.5" lower_limit="12.0" upper_limit="36.0"/>
                    <measurement group_id="O3" value="24.0" lower_limit="14.0" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.059</p_value>
            <p_value_desc>The p-value is for the comparison of the age cohorts (not including Total)</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Time to Resolution of Fever in Patients</param_type>
            <param_value>14.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>20</ci_upper_limit>
            <estimate_desc>Median time was estimated from the Kaplan-Meier curve (unstratified)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Decline of Body Temperature to the Afebrile State</title>
        <description>This was performed for all participants who had fever at baseline Fever is defined as body temperature &gt;37.0ÂºC. Rectal temperature is converted by subtracting 1 ÂºC. The rate of decline of body temperature was calculated as the slope of body temperature between the baseline temperature and the 1st temperature below 37Â°C. Participants with decline in body temperature were considered to have no fever; however, participants who did not show any decline in body temperature were considered to have persisting fever.</description>
        <time_frame>Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days</time_frame>
        <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Decline of Body Temperature to the Afebrile State</title>
          <description>This was performed for all participants who had fever at baseline Fever is defined as body temperature &gt;37.0ÂºC. Rectal temperature is converted by subtracting 1 ÂºC. The rate of decline of body temperature was calculated as the slope of body temperature between the baseline temperature and the 1st temperature below 37Â°C. Participants with decline in body temperature were considered to have no fever; however, participants who did not show any decline in body temperature were considered to have persisting fever.</description>
          <population>Pharmacodynamic Analysis Population consisted of all enrolled participants with a positive influenza infection confirmed by culture or PCR at baseline or anytime during the study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=33, 11, 4, decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, n=33, 11, 4, no decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, n=33, 11, 4, decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, n=33, 11, 4, no decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, n=33, 11, 4, decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, n=33, 11, 4, no decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18, n=16, 5, 1, decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18, n=16, 5, 1, no decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30, n=31, 9, 4, decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30, n=31, 9, 4, no decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Serious Adverse Events and Secondary Illness</title>
        <description>An Adverse Event (AEs) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect. Secondary illnesses were influenza disease-related events, namely bronchitis, pneumonia, otitis media, and sinusitis that resolved without sequelae. Adverse events, serious adverse events, and secondary illness are reported for on-treatment period (from the first dose of oseltamivir upto 3 days after the last dose of oseltamivir [Approximately 14 days].</description>
        <time_frame>Up to 3 days after the last dose of oseltamivir (Approximately 14 days)</time_frame>
        <population>Safety population included all treated participants with at least one post-baseline safety assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events, Serious Adverse Events and Secondary Illness</title>
          <description>An Adverse Event (AEs) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect. Secondary illnesses were influenza disease-related events, namely bronchitis, pneumonia, otitis media, and sinusitis that resolved without sequelae. Adverse events, serious adverse events, and secondary illness are reported for on-treatment period (from the first dose of oseltamivir upto 3 days after the last dose of oseltamivir [Approximately 14 days].</description>
          <population>Safety population included all treated participants with at least one post-baseline safety assessment</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with secondary illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Showing Within-patient Variability in Vital Signs</title>
        <description>Systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, and heart rate were examined for any consistent within-patient post-baseline changes.</description>
        <time_frame>Post baseline, Day 3, 4, 6, 11, 18+/- 2 days, 30+/-2 days</time_frame>
        <population>Safety population included all treated participants with at least one post-baseline safety assessment. Due to the small numbers of participants and the extent of influenza induced variability, changes in vital sign patterns cannot be detected.</population>
        <group_list>
          <group group_id="O1">
            <title>Oseltamivir 3 mg/kg</title>
            <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir 2.5 mg/kg</title>
            <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/kg twice a day for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 2 mg/kg</title>
            <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Showing Within-patient Variability in Vital Signs</title>
          <description>Systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, and heart rate were examined for any consistent within-patient post-baseline changes.</description>
          <population>Safety population included all treated participants with at least one post-baseline safety assessment. Due to the small numbers of participants and the extent of influenza induced variability, changes in vital sign patterns cannot be detected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 days after the last dose of oseltamivir (Approximately 14 days)</time_frame>
      <desc>SAEs and other AEs were collected in the safety population. Safety population included all treated participants with at least one post-baseline safety assessment. All AEs are reported for on-treatment period (from the first dose of oseltamivir up to 3 days after the last dose of oseltamivir [Approximately 14 days].</desc>
      <group_list>
        <group group_id="E1">
          <title>Oseltamivir 3 mg</title>
          <description>Participants aged 91 to &lt;365 days received oral suspension of oseltamivir 3 milligram (mg)/kilogram (kg) twice a day for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Oseltamivir 2.5 mg</title>
          <description>Participants of age 31 to 90 days received oral suspension of oseltamivir 2.5 mg/ twice a day for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Oseltamivir 2 mg</title>
          <description>Participants of age 0 to 30 days received oral suspension of oseltamivir 2 mg/kg twice a day for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Crepitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash maculoâpapular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsorâs intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

